By Meijer, D. K. F.; Molema, Grietje
Read Online or Download Drug targeting : organ-specific strategies PDF
Best general & reference books
The outline for this ebook, creation to suggestions and Theories in actual technological know-how, can be drawing close.
Black Powder production, trying out & Optimizing - by means of Ian von Maltitz. Examines black powder making from basic combined parts to complex, professional-type creation. Describes all parts and techniques. From chemistry to physics, from mechanical to mystical, together with examining components, reading options and approaches, from affordable to the easiest.
Content material: bankruptcy 1 complete Drying types in keeping with quantity Averaging: history, software and point of view (pages 1–55): Prof. Patrick Perree, Dr. Romain Remond and Prof. Ian W. TurnerChapter 2 Pore? community types: a strong instrument to review Drying on the Pore point and comprehend the effect of constitution on Drying Kinetics (pages 57–102): Thomas Metzger, Prof.
- Organic Reaction Mechanisms 1977
- Chemistry as a game of molecular construction : the bond-click way
- Structures and Mechanisms. From Ashes to Enzymes
- Novel Materials for Catalysis and Fuel Processing
- Stereoselective Synthesis: A Practical Approach
- The Chemistry of Photography
Extra resources for Drug targeting : organ-specific strategies
Viable Intellectual Property (IP) strategies ensure that invention-based research and development investments are protected. Strong IP protection is essential for the preservation and growth of a research-based enterprise, and thus for the sustained development of new and better medicines. Competition among research-based pharmaceutical companies is continually increasing. One company’s patent on a specific drug does not preclude other innovator companies from producing rival medicines to treat the same disease.
Growth is given relative to sales in 2000 . Brand name Ingredient Company Indication targets Sales (growth) [$ million] Nexium® Esomeprazole AstraZenec ulcers proton pump inhibitor 623 (999%) Protonix® Pantoprazole Altana/Wyeth ulcers proton pump inhibitor 695 (426%) Advair® Albuterol & Fluticasone GlaxoSmithKline β2 agonist & corticosteroid asthma 1103 (351%) Remicade® Infliximab J&J/Schering-Pl. 5 billion in 2001, thus claiming a market share of 6%. 9 billion). 7 billion. It is interesting to note that four classes grew more than 20% in 2001, namely the cholesterol reducers (22%), the antipsychotics (30%), the oral antidiabetics (30%), and the antihistamines (22%) .
The Tufts University Centre for the Study of Drug Development found that the time from synthesis of a new drug to US marketing approval has increased dramatically . 2). Lengthening development times dramatically increase the costs of bringing a new drug to market by increasing the capital needed for research and development activities. 2 Analysis of research and development timelines in recent years . The preclinical research, clinical development, and approval times are explicitly given.
Drug targeting : organ-specific strategies by Meijer, D. K. F.; Molema, Grietje